



View resources linking
sleep disorders and
cardiovascular health

Learn more

BECOME A MEMBER

VOLUNTEER

DONATE

JAHA

Journal of the American Heart Association

RESEARCH ARTICLE | Originally Published

Loss-Framed Personalized Activity Amount Using Wearable Devices in a Randomized Controlled Trial

Neel P. Chokshi, MD, MBA, Srinath Adusumilli, MD, PhD, BS, Charles A.L. Rareshide, MS, Victoria H. Chokshi, MD, PhD

Journal of the American Heart Association

Your Privacy

To give you the best possible experience we use cookies and similar technologies. We use data collected through these technologies for various purposes, including to enhance website functionality, remember your preferences, show the most relevant content, and show the most useful ads. You can select your preferences by clicking the link. For more information, please review our [Privacy & Cookie Notice](#)

[Manage Cookie Preferences](#)

Reject All Cookies

Accept All Cookies

Check for updates

Physical Activity in Ischemic Heart Disease Patients: The ACTIVE REWARD Trial

Neel P. Chokshi, MD, MBA, Srinath Adusumilli, MD, PhD, BS, Charles A.L. Rareshide, MS, Victoria H. Chokshi, MD, PhD

JAMA



PDF/EPUB

Abstract

Background

Regular physical activity reduces the risk of cardiovascular events, but most ischemic heart disease (IHD) patients do not obtain enough.

Methods and Results

ACTIVE REWARD (A Clinical Trial Investigating Effects of a Randomized Evaluation of Wearable Activity Trackers with Financial Rewards) was a 24-week home-based, remotely monitored, randomized trial with a 16-week intervention (8-week ramp-up incentive phase and 8-week maintenance incentive phase) and an 8-week follow-up. Patients used wearable devices to track step counts and establish a baseline. Patients in control received no other interventions. Patients in the incentive arm received personalized step goals and daily feedback for all 24 weeks. In the ramp-up incentive phase, daily step goals increased weekly by 15% from baseline with a maximum of 10 000 steps and then remained fixed. Each week, \$14 was allocated to a virtual account; \$2 could be lost per day for not achieving step goals. The primary outcome was change in mean daily steps from baseline to the maintenance incentive phase. Ischemic heart disease patients had a mean (SD) age of 60 (11) years and 70% were male. Compared with control, patients in the incentive arm had a significantly greater increase in mean daily steps from baseline during ramp-up (1388 versus 385; adjusted difference, 1061 [95% confidence interval, 386–1736]; $P<0.01$), maintenance (1501 versus 264; adjusted difference, 1368 [95% confidence interval, 571–2164]; $P<0.001$), and follow-up (1066 versus 92; adjusted difference, 1154 [95% confidence interval, 282–2027]; $P<0.01$).

Conclusions

Loss-framed financial incentives with personalized goal setting significantly increased physical activity among ischemic heart disease patients using wearable devices during the 16-week intervention, and effects were sustained during the 8-week follow-up.



Now Reading:

Loss-Framed Financial Incentives and Personalized Goal-Setting to Increase Physical...



PDF/EPUB



Clinical Perspective

What Is New?

- Despite the many benefits of exercise-based cardiac rehabilitation, many patients do not participate in exercise-based cardiac rehabilitation on their own.
- We evaluated a scalable intervention for IHD patients by using insights from behavioral economics to address predictable barriers to behavior change and monitor behaviors.
- The combination of loss-framed financial incentives and goal setting significantly increased physical activity in IHD patients.

What Are the Clinical Implications?

- Providing only wearable devices is not sufficient to achieve significant changes in physical activity in IHD patients.
- Combining approaches based on behavioral economics to deploy home-based interventions can be used to increase physical activity in IHD patients.

Your Privacy

To give you the best possible experience we use cookies and similar technologies. We use data collected through these technologies for various purposes, including to enhance website functionality, remember your preferences, show the most relevant content, and show the most useful ads. You can select your preferences by clicking the link. For more information, please review our [Privacy & Cookie Notice](#)

[Manage Cookie Preferences](#)

Reject All Cookies

Accept All Cookies

tients do not
on their own.
disease
d goal setting
remotely

ificantly

to significant

can be used
ic heart

Ischemic heart disease (IHD) is a leading cause of death in the United States.¹ Regular physical activity reduces the risk of IHD.² However, many patients do not participate in exercise-based cardiac rehabilitation on their own.³ For example, participation in exercise-based cardiac rehabilitation has been demonstrated to reduce mortality by up to 30%.⁴ However, the majority of eligible patients do not participate in a cardiac rehabilitation program.⁵ Recent evidence also suggests that IHD patients do not often achieve physical activity goals on their own.¹²

Wearable devices have received significant attention for their ability to remotely monitor health behaviors such as physical activity.¹³ However, thus far there is limited evidence of interventions that use these devices to effectively sustain behavior change among high-risk patients.¹³ Our previous work found that financial incentive-based approaches that use mobile technologies can be effective in increasing physical activity,¹⁷ but only if they are designed to appropriately leverage insights from behavioral economics—a field that incorporates insights from psychology to design interventions that address predictable barriers to behavior change.²⁰ For example, we found that the framing of financial incentives significantly impacted their effectiveness.¹⁸ A “gain-framed” incentive that used the standard economic approach of rewarding individuals only after physical activity goals were achieved was not effective. However, a “loss-framed” financial incentive that allocated money upfront to a virtual account, which could be lost if goals were not achieved, led to a 50% relative increase in physical activity.

In this study, our objective was to use a randomized controlled trial to test the effectiveness of loss-framed financial incentives with personalized goal setting to increase physical activity among IHD patients. We tested a potentially scalable design that recruited patients from 4 hospitals and delivered home-based interventions remotely by using wearable devices and an automated technology platform.²²

Methods

The data, analytical methods, and study materials will not be made available to other researchers for purposes of reproducing the results or replicating the procedure.

Study Design

ACTIVE REWARD (A Clinical Trial Investigating Effects of a Randomized Evaluation of Wearable Activity trackers with Financial Rewards) was a randomized controlled trial conducted between

The study protocol (Data ^{S1}) was approved by the University of Pennsylvania (Philadelphia, PA) Institutional Review Board, and participants provided informed consent.

The study was conducted using Way to Health, a research technology platform at the University of Pennsylvania used previously for physical activity interventions.¹⁷ Patients used the study website to create an account, provide informed consent online, and completed baseline eligibility surveys and the MacNew he ected whether ing, or a Misfit Shine) onstrated that

All patients received \$20 for were allowed to keep the we mailed a bank check at the end of each mc

Study Sample

Recruitment occurred from I southeastern Pennsylvania: Center, Chester County Hos eligible for, but not yet enrol recent cardiac catheterizati by telephone or during cardi were aged ≥18 years, had a segment–elevation myocard

coronary catheterization for suspected ischemic heart disease that resulted in a definitive diagnosis. After enrollment, we used data from the electronic health record to check for the presence of IHD. Patients were excluded if they were already enrolled in a formal cardiac rehabilitation program within the past 1 year, did not have access to a smartphone or tablet compatible with the wearable device, were admitted to the hospital and were not being discharged to home, or had any other reason that participation was unsafe (eg, hemodynamic instability or New York Heart Association Class III–IV heart failure) or infeasible (eg, inability to provide informed consent).

Baseline Step Count

Before randomization, patients were told to spend 2 weeks getting accustomed to their device. During this run-in period, we estimated a baseline step count using the second week of data—a method used in previous work.²⁵ The first week of data was ignored to diminish the potential upward bias of the estimate from higher activity during initial device use. To prevent potential mismeasurement, we ignored any daily values less than 1000 steps because evidence indicates that these values are unlikely to represent capture of actual activity.²⁶ If less than 4 days of data were available during the second week (n=5), the patient was contacted to inquire about any device issues and the run-in period was expanded until at least 4 days of data were captured.

Randomization

Patients with a baseline step count were then electronically randomized to a study arm using block sizes of 4, stratified by age (<65 years versus ≥65 years). All investigators, statisticians, and data analysts were blinded to arm assignments until the study and analysis were completed.

Interventions

Patients in the control arm had their step counts passively monitored by the wearable device, but were not informed of their baseline step count. The wearable device was preset with the goal of 10 000 steps per day and could be adjusted by the patient. The wearable device displayed progress toward that goal using a circular dial, and actual step counts were available within the smartphone application. Patients in this arm received no other interventions.

Patients in the incentive arm received daily feedback on their performance for all 24 weeks. In the

Your Privacy

To give you the best possible experience we use cookies and similar technologies. We use data collected through these technologies for various purposes, including to enhance website functionality, remember your preferences, show the most relevant content, and show the most useful ads. You can select your preferences by clicking the link. For more information, please review our [Privacy & Cookie Notice](#)

[Manage Cookie Preferences](#)

Reject All Cookies

Accept All Cookies

g 4 hospitals in yterian Medical ed patients i patients with a vere contacted ipate if they non–ST- rction), or had

ek trial, and mailed a bank

during the maintenance incentive phase (weeks 9–16) and the follow-up phase without incentives (weeks 17–24). During the 16-week intervention, patients were offered a loss-framed financial incentive. Each week, patients were informed upfront that \$14 was allocated to a virtual account. Each day the patient achieved his or her step goal, the balance remained unchanged, but each day the step goal was not achieved, the patient was informed that \$2 had been deducted. The balance was refreshed with \$14 every week on Monday. This design leveraged 4 important psychological principles: Immediate over delayed gratification, loss aversion, goal priming, and the fresh start effect.³⁴

After the 16-week intervention, patients completed a self-reported survey about their perceptions of the overall study experience.

Outcome Measures

The primary outcome was change in mean daily steps from baseline to the end of the maintenance incentive phase and follow-up phase.

Statistical Analysis

Power calculations (a priori) were conducted assuming a mean daily step count of 6000 steps in the control group, a 1000-step difference in the intervention group, a two-sided α of 0.05. It was estimated that 100 patients would provide 80% power to detect a 1000-step difference between the incentive and control arms in the change in mean daily steps from baseline to the maintenance incentive phase. However, enrollment was closed with 105 patients because of funding constraints on the timeline. Based on these same assumptions, we had at least 80% power to detect a 1200-step difference.

All randomly assigned patients were included in the intention-to-treat analysis. For each patient on each day of the study (patient-day level), the number of steps achieved was obtained as a continuous variable. Data could be missing for any day if a patient did not use the activity tracking device or did not upload data. One patient had very high step counts compared to others in the study. After investigation, we learned that the patient frequently played the drums and there have been reports of inaccurate step tracking from this activity.³⁵ Therefore, all of this patient's data were deemed invalid and classified as missing. For the prespecified main analysis, we used multiple imputation for data that were missing and step values less than 1000. We have used this method in previous work¹⁷ and in this study because evidence indicates that step values less than 1000 may not represent accurate data capture.²⁶ Five imputations were conducted using the mice package in R (R Foundation for Statistical Computing, Vienna, Austria), which allows for patient random effects with this data structure.³⁷ The following predictors of missing data were included: study arm, week of study, calendar month, baseline step count, age, sex, race/ethnicity, education, marital status, household income, body mass index, days since last cardiac catheterization, most recent ejection fraction, and history of diabetes mellitus, hypertension, hyperlipidemia, smoking, and valvular heart disease. Results were combined using Rubin's standard rules.³⁸ Secondary analyses were conducted using collected data without multiple imputation, both with and without step values less than 1000.

Unadjusted analyses estimated the change in mean daily steps from baseline to each week and each phase (ramp-up, maintenance, and follow-up) of the study. In adjusted analyses, we used PROC GLIMMIX in SAS (SAS Institute Inc, Cary, NC) to fit linear mixed-effects models with a random intercept, patient random effects, and to account for the repeated measures of daily step counts. In the main model, we included baseline step count and fixed effects for calendar month and study arm. To test the robustness of our findings, we also fit a fully adjusted model that included age, sex, race/ethnicity, education, marital status, household income, body mass index, days since last cardiac catheterization, most recent ejection fraction, and history of diabetes mellitus, hypertension, hyperlipidemia, smoking, and valvular heart disease.

Your Privacy

To give you the best possible experience we use cookies and similar technologies. We use data collected through these technologies for various purposes, including to enhance website functionality, remember your preferences, show the most relevant content, and show the most useful ads. You can select your preferences by clicking the link. For more information, please review our [Privacy & Cookie Notice](#)

[Manage Cookie Preferences](#)

Reject All Cookies

Accept All Cookies

...¹⁸ favor
...d to be more
...of the week

...e asked to
...rehabilitation,
...mission) and

...nance incentive
...ramp-up

...ne mean step
...rate, and a 2-
...ensure at least



maintenance, and follow-up) using the least squares means (LSMEANS) command. In a post-hoc exploratory subgroup analysis, we evaluated effects in patients with recent care for IHD by fitting the same models for only patients who had a cardiac catheterization within the 90 days preceding enrolling in the study.

Hypothesis tests were 2-sided using a significance level of 0.05. Analyses were conducted in SAS (version 9.4; SAS Institute Inc., Cary, NC). Statistical significance was defined as $P < .05$.


Your Privacy

Results

In this trial, 105 patients with a history of IHD (mean age 60 years, 70% were male, and 30% were female) underwent cardiac catheterization. Baseline patient characteristics are shown in Table 1. Baseline mean daily steps were 4,324 (SD, 3,246) in the control arm, which was not significantly different from the incentive arm.

To give you the best possible experience we use cookies and similar technologies. We use data collected through these technologies for various purposes, including to enhance website functionality, remember your preferences, show the most relevant content, and show the most useful ads. You can select your preferences by clicking the link. For more information, please review our [Privacy & Cookie Notice](#)

(SD) age of 60 years, 70% were male, and 30% were female. Baseline mean daily steps were 4,324 (SD, 3,246) in the control arm, which was not significantly different from the incentive arm.



| Table 1 Characteristics of the Study Sample | | | |
|---|--------------------|----------------------|---------|
| Characteristic | Control Arm (n=55) | Incentive Arm (n=50) | P Value |
| Sociodemographics | | | |

| Characteristic | Control Arm (n=55) | Incentive Arm (n=50) | P Value |
|-------------------------|--------------------|----------------------|---------|
| Race/ethnicity, no. (%) | | | 0.46 |

EXPAND TABLE

Health-related quality of life score obtained from the MacNew Survey. IQR indicates interquartile range.

One hundred three patients period, 22.0% of observation control arm, these rates were less than 1000 (Table [S1](#)).

In the control arm, the unadjusted mean change in daily steps during the first 6 weeks, but the incentive arm, the unadjusted mean change in daily steps from baseline remained in the follow-up period ranging

Your Privacy

To give you the best possible experience we use cookies and similar technologies. We use data collected through these technologies for various purposes, including to enhance website functionality, remember your preferences, show the most relevant content, and show the most useful ads. You can select your preferences by clicking the link. For more information, please review our [Privacy & Cookie Notice](#)

[Manage Cookie Preferences](#)

aintenance
n 1000. In the
step counts

near 500
(Figure [2](#)). In
above 1000 in
range in daily
significantly declined




Figure 2 Central illustration, Unadjusted mean change in daily steps from baseline by study arm and week. Data presented are the difference between mean daily steps and mean baseline steps by week for each arm. Gray solid line represents patients in the control arm. Black dashed line represents patients in the financial incentive arm. Solid vertical gray lines represent the end of each study phase.

In the main adjusted model compared with control, patients in the incentive arm had a significantly greater increase in mean daily steps from baseline during ramp-up (1388 versus 385; adjusted difference, 1061 [95% confidence interval [CI], 386–1736]; $P<0.01$), maintenance (1501 versus 264; adjusted difference, 1368 [95% CI, 571–2164]; $P<0.001$), and follow-up (1066 versus 92; adjusted difference, 1154 [95% CI, 282–2027]; $P<0.01$). Results were qualitatively similar in the fully adjusted model (Table [2](#)) and in secondary analyses that used collected data (Tables [S2](#) and [S3](#)).

| | Baseline | Ramp-up (Weeks 1–8) | Maintenance (Weeks 9–16) | Follow-up (Weeks 17–24) |
|--------------------------|----------------|------------------------|-----------------------------|----------------------------|
| Steps per day, Mean (SD) | | | | |
| Control arm | 6577 (3084) | 6962 (3364) | 6841 (3254) | 6669 (3091) |
| Incentive arm | | | | 3271 (3003) |

Main model

Models compare the incentive arm to control. Main model adjusts for baseline characteristics. We also added the following covariates: age, sex, index, days since last cardiac catheterization, hypertension, hyperlipidemia, smoking status, and comorbidities.

Your Privacy

To give you the best possible experience we use cookies and similar technologies. We use data collected through these technologies for various purposes, including to enhance website functionality, remember your preferences, show the most relevant content, and show the most useful ads. You can select your preferences by clicking the link. For more information, please review our [Privacy & Cookie Notice](#)

[Manage Cookie Preferences](#)

Reject All Cookies

Accept All Cookies

is command.

adjusted model

ne, body mass

ilitus,

Seventy-eight patients (74.3% of the incentive arm) within the 90 days preceding enrollment compared with control, patients had a mean increase in daily steps from baseline during the ramp-up phase [466–1797]; $P<0.001$), maintenance phase [2297]; $P<0.001$), and follow-up phase [1154]; $P<0.001$; Table [S4](#)).

No adverse events were reported. The mean cost of incentives was \$5194, which averaged \$103.88 per patient. Self-reported healthcare utilization was similar between arms (Tables [S5](#) and [S6](#)). By the end of the intervention, only 8 patients (3 in control and 5 in the incentive arm) reported joining a formal cardiac rehabilitation program. Most patients reported positive perceptions of their experience in the study, but more patients in the incentive arm agreed that they would continue to use the wearable device after the study completed (83.8% versus 5.8%; Table [S7](#)).

Discussion

In this trial, we found that loss-framed financial incentives with personalized goal setting and wearable devices significantly increased physical activity among IHD patients over a 6-month period including 8 weeks of follow-up without incentives. To our knowledge, this is 1 of the first studies to demonstrate the successful use of financial incentives and wearable devices to increase physical activity among this high-risk population. Subset analyses found similar results among the 74% of patients who had recent care for IHD as indicated by a cardiac catheterization within the 90 days preceding enrolling in the study. This intervention remotely monitored patients using an automated technology platform and wearable devices and therefore has the potential to be scaled more broadly.

Our findings reveal several important implications for future intervention design. First, a key element of our study design was the use of loss aversion, a principle from behavioral economics.^{[13](#)} Most previous financial incentive-based physical activity interventions have used gain-framed incentives^{[16](#)}—individuals earn a reward after the behavior is achieved. However, our previous work among overweight and obese individuals found that loss-framed incentives were more effective than gain-framed incentives.^{[18](#)} Results from this trial confirm that loss-framed incentives can significantly increase physical activity among high-risk cardiovascular disease patients. We also found that loss-framed incentives led to sustained effects during the 8-week follow-up without incentives (1154 more steps). Whereas physical activity in the incentive arm declined slightly from maintenance to follow-up, activity during both periods was higher than during the ramp-up phase (1061 more steps). It is also important to note that physical activity levels in the control arm declined over time, most rapidly during the follow-up phase.



Future studies could also evaluate financial incentives and personalized feedback independently to assess differential effects.

Second, our approach to goal setting was unique from most previous financial incentive-based intervention studies. Many physical activity interventions that use incentives are designed with static step goals that ask individuals to immediately achieve large step increases.¹⁶ In this trial, we used a ramp-up phase to increase step goals (from 1,000 to 10,000 steps per week) and personalized these goals to each participant's baseline activity. This approach mirrors that of cardiac rehabilitation programs, which gradually increase step goals.

Third, this trial used a home-based approach, which was scaled more broadly by leveraging technology for cardiac rehabilitation, but only 7.6% of patients completed the intervention. Nationally, cardiac rehabilitation programs do not substitute for cardiac rehabilitation, and physical activity in patients who are enrolled in cardiac rehabilitation programs can build upon this approach to increase physical activity.

Our study is subject to several limitations. First, the study was conducted in Pennsylvania and needed additional validation in other populations. Second, we evaluated physical activity measures of physical activity, which are most commonly displayed in clinical outcomes across different populations.⁴³ Future studies could evaluate both changes in step counts and other clinical outcomes over longer periods. Third, the control arm had slightly higher missing data rates than the incentive arm. However, our imputation and regression models both used patient random effects to adjust for differential variation across patients and arms. We also found similar results when using imputed and nonimputed data. Fourth, whereas effects were sustained during follow-up, daily feedback was continued and physical activity did decline slightly. Further evaluations are needed to determine longer-term sustainability. Fifth, the control arm did not receive daily feedback or personalized goal setting, and so we were unable to isolate the effects of the financial incentive alone. Sixth, in this study, loss-framed incentives were compared with control and not with gain-framed incentives. Future studies could compare different ways to frame incentives in this study population to increase physical activity.

Conclusions

In this home-based, remotely monitored trial of IHD patients using wearable devices, loss-framed financial incentives with personalized goal setting significantly increased physical activity during the 16-week intervention, and effects were sustained during the 8-week follow-up. Our findings demonstrate that digital health interventions that leverage insights from behavioral economics offer a promising approach to change health behaviors among patients with cardiovascular disease.

Sources of Funding

This study was supported, in part, by grant number UL1TR000003 from the National Center for Advancing Translational Science. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Center for Advancing Translational Science or the National Institutes of Health. The study was also supported, in part, by the Institute for Translational Medicine and Therapeutics (ITMAT) and the University of Pennsylvania Health System through the Penn Medicine Nudge Unit. Misfit Inc donated some of the wearable devices used in this study. The funding sources had no role in the design and conduct of the

Your Privacy

To give you the best possible experience we use cookies and similar technologies. We use data collected through these technologies for various purposes, including to enhance website functionality, remember your preferences, show the most relevant content, and show the most useful ads. You can select your preferences by clicking the link. For more information, please review our [Privacy & Cookie Notice](#)

[Manage Cookie Preferences](#)

Reject All Cookies

Accept All Cookies



Now Reading:

Loss-Framed Financial Incentives and Personalized Goal-Setting to Increase Physical...



PDF/EPUB



Disclosures

Dr Patel is supported by career development awards from the Department of Veterans Affairs HSR&D and the Doris Duke Charitable Foundation. Dr Patel is founder of Catalyst Health, a technology and behavior change consulting firm. Dr Patel also has received research funding from Deloitte, which is not related to the work described in this article. Ms Ha was supported by a T32 grant from the National Institutes of Health. The authors have no disclosures to report.

Your Privacy

To give you the best possible experience we use cookies and similar technologies. We use data collected through these technologies for various purposes, including to enhance website functionality, remember your preferences, show the most relevant content, and show the most useful ads. You can select your preferences by clicking the link. For more information, please review our [Privacy & Cookie Notice](#)

[Manage Cookie Preferences](#)

Reject All Cookies

Accept All Cookies

Supplemental Material

File (jah33227-sup-0001-supinData **S1.** Study Protocol.
Table S1. Missing Data Rates by
Table S2. Physical Activity Outcome
Table S3. Physical Activity Outcome
Step Values Less Than 1000
Table S4. Physical Activity Outcome
Days Preceding Enrolling in the
Table S5. Patients' Self-Reported
Table S6. Patients' Self-Reported
Table S7. Patients' Perceptions

Download

333.33 KB

References

1. Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, de Ferranti S, Després JP, Fullerton HJ, Howard VJ, Huffman MD, Judd SE, Kissela BM, Lackland DT, Lichtman JH, Lisabeth LD, Liu S, Mackey RH, Matchar DB, McGuire DK, Mohler ER III, Moy CS, Muntner P, Mussolino ME, Nasir K, Neumar RW, Nichol G, Palaniappan L, Pandey DK, Reeves MJ, Rodriguez CJ, Sorlie PD, Stein J, Towfighi A, Turan TN, Virani SS, Willey JZ, Woo D, Yeh RW, Turner MB; American Heart Association Statistics Committee and Stroke Statistics Subcommittee . Heart disease and stroke statistics—2015 update: a report from the American Heart Association. *Circulation*. 2015;131:e29–e322.

Show Citations

Crossref

PubMed

Google Scholar

2. Murray CJ, Atkinson C, Bhalla K, Birbeck G, Burstein R, Chou D, Dellavalle R, Danaei G, Ezzati M, Fahimi A, Flaxman D, Foreman, Gabriel S, Gakidou E, Kassebaum N, Khatibzadeh S, Lim S, Lipshultz SE, London S, Lopez, MacIntyre MF, Mokdad AH, Moran A, Moran AE, Mozaffarian D, Murphy T, Naghavi M, Pope C, Roberts T, Salomon J, Schwebel DC, Shahrzad S, Sleet DA, Murray, Abraham J, Ali MK, Atkinson C, Bartels DH, Bhalla K, Birbeck G, Burstein R, Chen H, Criqui MH, Dahodwala, Jarlais, Ding EL, Dorsey ER, Ebel BE, Ezzati M, Fahimi, Flaxman S, Flaxman AD, Gonzalez-Medina D, Grant B, Hagan H, Hoffman H, Kassebaum N, Khatibzadeh S, Leasher JL, Lin J, Lipshultz SE, Lozano R, Lu Y, Mallinger L, McDermott MM, Micha R, Miller TR, Mokdad AA, Mokdad AH, Mozaffarian D, Naghavi M, Narayan KM, Omer SB, Pelizzari PM, Phillips D, Ranganathan D, Rivara FP, Roberts T, Sampson U, Sanman E, Sapkota A, Schwebel DC, Sharaz S, Shivakoti R, Singh GM, Singh D, Tavakkoli M, Towbin JA, Wilkinson JD, Zabetian A, Murray, Abraham J, Ali MK, Alvarado M, Atkinson C, Baddour LM, Benjamin EJ, Bhalla K, Birbeck G, Bolliger I, Burstein R, Carnahan E, Chou D, Chugh SS, Cohen A, Colson KE, Cooper LT, Couser W, Criqui MH, Dabhadkar KC, Dellavalle RP, Jarlais, Dicker D, Dorsey ER, Duber H, Ebel BE, Engell RE, Ezzati M, Felson DT, Finucane MM, Flaxman S, Flaxman AD, Fleming T, Foreman, Forouzanfar MH, Freedman G, Freeman MK, Gakidou E, Gillum RF, Gonzalez-Medina D, Gosselin R, Gutierrez HR, Hagan H, Havmoeller R, Hoffman H, Jacobsen KH, James SL, Jasrasaria R, Jayarman S, Johns N, Kassebaum N, Khatibzadeh S, Lan Q, Leasher JL, Lim S, Lipshultz SE, London S, Lopez, Lozano R, Lu Y, Mallinger L, Meltzer M, Mensah GA, Michaud C, Miller TR, Mock C, Moffitt TE, Mokdad AA, Mokdad AH, Moran A, Naghavi M, Narayan KM, Nelson RG, Olives C, Omer SB, Ortblad K, Ostro B, Pelizzari PM, Phillips D, Raju M, Razavi H, Ritz B, Roberts T, Sacco RL, Salomon J, Sampson U, Schwebel DC, Shahrzad S, Shibuya K, Silberberg D, Singh JA, Steenland K, Taylor JA, Thurston GD, Vavilala MS, Vos T, Wagner GR, Weinstock MA, Weisskopf MG, Wulf S, Murray; U.S. Burden of Disease Collaborators . The state of US health, 1990–2010: burden of diseases, injuries, and risk factors. *JAMA*. 2013;310:591–608.

Go to Citation

Crossref

PubMed

Google Scholar

3. Thompson PD, Buchner D, Pina IL, Balady GJ, Williams MA, Marcus BH, Berra K, Blair SN, Costa F, Franklin B, Fletcher B,



Now Reading:

Loss-Framed Financial Incentives and Personalized Goal-Setting to Increase Physical...



PDF/EPUB



(Subcommittee on Exercise, Rehabilitation, and Prevention) and the Council on Nutrition, Physical Activity, and Metabolism (Subcommittee on Physical Activity). *Circulation*. 2003;107:3109–3116.

[Go to Citation](#) | [Crossref](#) | [PubMed](#) | [Google Scholar](#)

4. O'Connor GT, Buring JE, Yusuf S, Goldhaber SZ, Olmstead EM, Paffenbarger RS, Hennekens CH. An overview of randomized trials of rehabilitation with exercise after myocardial infarction. *Circulation*. 1989;80:234–244.

[Go to Citation](#) | [Crossref](#)

Your Privacy

To give you the best possible experience we use cookies and similar technologies. We use data collected through these technologies for various purposes, including to enhance website functionality, remember your preferences, show the most relevant content, and show the most useful ads. You can select your preferences by clicking the link. For more information, please review our [Privacy & Cookie Notice](#)

[Manage Cookie Preferences](#)

Reject All Cookies

Accept All Cookies

eLetters

eLetters should relate to an article, providing unpublished data. Comments are not peer-reviewed. Comments are not published if they are longer than 500 words and do not cite an article cited in the comment.

Comments and feedback on the AHA/ASA Manuscript Overview are welcome.

 SIGN IN TO SUBMIT A RESPONSE

Forum for discussion and language. Comments are website only. Comments should be no longer than 500 words. Authors of the article are not responsible for the content of the comments.

Comments will be directed to the author of the article.



Now Reading:

Loss-Framed Financial Incentives and Personalized Goal-Setting to Increase Physical...



PDF/EPUB





Your Privacy

To give you the best possible experience we use cookies and similar technologies. We use data collected through these technologies for various purposes, including to enhance website functionality, remember your preferences, show the most relevant content, and show the most useful ads. You can select your preferences by clicking the link. For more information, please review our [Privacy & Cookie Notice](#)

[Manage Cookie Preferences](#)

Reject All Cookies

Accept All Cookies



Now Reading:

Loss-Framed Financial Incentives and Personalized Goal-Setting to Increase Physical...



PDF/EPUB





Your Privacy

To give you the best possible experience we use cookies and similar technologies. We use data collected through these technologies for various purposes, including to enhance website functionality, remember your preferences, show the most relevant content, and show the most useful ads. You can select your preferences by clicking the link. For more information, please review our [Privacy & Cookie Notice](#)

[Manage Cookie Preferences](#)

Reject All Cookies

Accept All Cookies

Journal of the American



SUBMIT

BROWSE

- [Collections](#)
- [Subject Terms](#)
- [AHA Journal Podcasts](#)
- [Trend Watch](#)

RESOURCES

- [CME](#)
- [DEIA Resources](#)
- [Early Career Resources](#)
- [AHA Journals @ Meetings](#)

INFORMATION

- [For Authors](#)
- [For Reviewers](#)
- [For Subscribers](#)
- [For International Users](#)

- [Arteriosclerosis, Thrombosis, and Vascular Biology](#)
- [Circulation](#)
- [Circulation Research](#)
- [Hypertension](#)
- [Stroke](#)

- [Journal of the American Heart Association](#)
- [Circulation: Arrhythmia and Electrophysiology](#)
- [Circulation: Cardiovascular Imaging](#)
- [Circulation: Cardiovascular Interventions](#)
- [Circulation: Cardiovascular Quality & Outcomes](#)

- [Circulation: Genomic and Precision Medicine](#)
- [Circulation: Heart Failure](#)
- [Stroke: Vascular and Interventional Neurology](#)
- [Annals of Internal Medicine: Clinical Cases](#)



National Center
7272 Greenville Ave.Dallas, TX 75231

Customer Service
1-800-AHA-USA-1
1-800-242-8721

Hours



PDF/EPUB



ABOUT US

[About the AHA/ASA](#)

[Annual report](#)

[AHA Financial Information](#)

[Careers](#)

[International Programs](#)

[Latest Heart and Stroke News](#)

[AHA/ASA Media Newsroom](#)

GET INVOLVED

› [Donate](#)

› [Advocate](#)

› [Volunteer](#)

› [ShopHeart](#)

› [ShopCPA](#)

›

›

OUR SITES

› [American Heart Association](#)

› [American Stroke Association](#)

› [AHA & ASA](#)

›

›

›

›

Your Privacy

To give you the best possible experience we use cookies and similar technologies. We use data collected through these technologies for various purposes, including to enhance website functionality, remember your preferences, show the most relevant content, and show the most useful ads. You can select your preferences by clicking the link. For more information, please review our [Privacy & Cookie Notice](#)

[Manage Cookie Preferences](#)

Reject All Cookies

Accept All Cookies

[AHA Careers](#) | [Privacy Policy](#)
[Conflict of Interes Policy.](#) | [Linking.F](#)

[/Statement](#) | [Ethics Policy](#) |
[Diversity.](#) | [Suppliers & Providers](#) |

©2022 American Heart Association. All rights reserved.

The American Heart Association is a 501(c)(3) nonprofit organization.

*Red Dress [™] DHHS, Go Red [™] AHA ; National Wear Red Day[®] is a registered trademark.